Cartography Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cartography Biosciences, Inc. - overview
Established
2020
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2020 by its CEO Kevin Parker, and co-founders Howard Chang, and Ansu Satpathy, Cartography Biosciences, Inc. operates as a therapeutics company that provides medicine for immuno-oncology and cancers. In October 2025, Cartography Biosciences, Inc. raised USD 67 million in series B funding led by new investor Pfizer Venture Investments, with participation from other new investors LG Corp, Amgen Ventures, Finchley Healthcare Ventures, Global BioAccess Fund, and Lotte Holdings CVC.
Returning investors Andreessen Horowitz, 8VC, Wing, Catalio Capital Management, AME Cloud Ventures, ARTIS Ventures, and Gaingels also participated in the round. Cartography Biosciences, Inc. offers a platform that integrates cutting-edge computational and experimental techniques, including single-cell genomics and proteomics to create immunotherapies by identifying the targets that maximize efficacy, and analyze cancers while minimizing potentially toxic side effects. Cartography Biosciences, Inc.
will use the October 2025 funding to move its lead cancer drug CBI-1214 into clinical trials and develop other antibody therapies from its ATLAS and SUMMIT platforms.
Current Investors
Alexandria Venture Investments, ARTIS Ventures, Andreessen Horowitz
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.cartography.bio
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.